RT Journal Article
SR Electronic
T1 Distribution equality as an optimal epidemic mitigation strategy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.15.20194506
DO 10.1101/2020.09.15.20194506
A1 Hacohen, Adar
A1 Cohen, Reuven
A1 Efroni, Sol
A1 Bachelet, Ido
A1 Barzel, Baruch
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.09.15.20194506.abstract
AB Upon the development of a drug or vaccine, a successful response to a global pandemic, such as COVID-19, requires the capacity for efficient distribution at a global scale. Considering constraints on production and shipping, most existing strategies seek to maximize the outflow of therapeutics, hence optimizing for rapid dissemination. Surprisingly, we find that this intuitive approach is counterproductive. The reason is that focusing strictly on the quantity of disseminated therapeutics, such strategies disregard their specific spreading patterns, most crucially – they overlook the interplay of these spreading patterns with those of the pathogens. This results in a discrepancy between supply and demand, that prohibits efficient mitigation even under optimal conditions of superfluous drug/vaccine flow. Therefore, here, we design a dissemination strategy that naturally follows the predicted spreading patterns of the epidemic, optimizing not just for supply volume, but also for its congruency with the anticipated demand. Specifically, we show that epidemics spread relatively uniformly across all destinations, and hence we introduce an equality constraint into our dissemination that prioritizes supply homogeneity. This strategy may, at times, slow down the supply rate in certain locations, however, thanks to its egalitarian nature, which mimics the flow of the viral spread, it provides a dramatic leap in overall mitigation efficiency, saving more lives with orders of magnitude less resources.Competing Interest StatementThe authors have declared no competing interest.Funding Statement This research was supported by the Israel Science Foundation grant no. 499/19 and by the Israel Council for Higher Education (VATAT) Grant for data science research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon publication, the authors plan to make all datasets and numerical codes publicly available.